SUBSCRIBE
SUBSCRIBE
News   Drug Development

EU Backs GlaxoSmithKline’s Breast Cancer Drug with Warnings

April 24, 2008 | 
1 min read
LONDON, April 24 (Reuters) - European drug regulators said on Thursday they recommended approval of GlaxoSmithKline Plc's new breast cancer pill Tykerb, or Tyverb, but with additional warnings about potential liver toxicity.
Clinical research Postmarket research Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie
illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
 · 
3 min read
 · 
Annalee Armstrong